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Aberrant glucose metabolism is one of the hallmarks of cancer
that facilitates cancer cell survival and proliferation. Here, we
demonstrate that MUC1, a large, type I transmembrane protein
that is overexpressed in several carcinomas including pancreatic
adenocarcinoma, modulates cancer cell metabolism to facilitate
growth properties of cancer cells. MUC1 occupies the promoter
elements of multiple genes directly involved in glucose metabolism and regulates their expression. Furthermore, MUC1 expression enhances glycolytic activity in pancreatic cancer cells. We also
demonstrate that MUC1 expression enhances in vivo glucose
uptake and expression of genes involved in glucose uptake and
metabolism in orthotopic implantation models of pancreatic
cancer. The MUC1 cytoplasmic tail is known to activate multiple
signaling pathways through its interactions with several transcription factors/coregulators at the promoter elements of various
genes. Our results indicate that MUC1 acts as a modulator of the
hypoxic response in pancreatic cancer cells by regulating the
expression/stability and activity of hypoxia-inducible factor-1α
(HIF-1α). MUC1 physically interacts with HIF-1α and p300 and stabilizes the former at the protein level. By using a ChIP assay, we
demonstrate that MUC1 facilitates recruitment of HIF-1α and p300
on glycolytic gene promoters in a hypoxia-dependent manner.
Also, by metabolomic studies, we demonstrate that MUC1 regulates multiple metabolite intermediates in the glucose and amino
acid metabolic pathways. Thus, our studies indicate that MUC1
acts as a master regulator of the metabolic program and facilitates
metabolic alterations in the hypoxic environments that help tumor
cells survive and proliferate under such conditions.
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UC1, a type I transmembrane protein, plays a signiﬁcant
role in the progression of cancer, particularly pancreatic
adenocarcinoma (1–4). Although expressed in the normal pancreas, its expression is elevated in pancreatic adenocarcinoma
and its expression pattern changes from a strictly apical localization on normal polarized epithelial cells to a broad distribution
across the cell surface membrane of nonpolarized tumor cells
(2). This results in aberrant signaling that enhances tumor progression and metastasis. MUC1 protein is expressed in >90% of
pancreatic tumors (5), and MUC1 expression in tumors and its
serum levels are associated with a poor prognosis and recurrence
in patients with resected tumors (6). Much of the oncogenic role
of MUC1 can be attributed to the participation of the small,
cytoplasmic tail of MUC1 (MUC1.CT) in signal transduction
and transcriptional events (2). ChIP-chip analyses have demonstrated that MUC1 occupies a plethora of promoter elements
in which MUC1 modulates the recruitment and activity of
www.pnas.org/cgi/doi/10.1073/pnas.1203339109

transcription factors, thus regulating transcription of the corresponding genes (7).
Several studies have established a role for MUC1 in tumor
growth, invasion and metastasis in pancreatic cancer (4, 8, 9).
MUC1 expression signiﬁcantly correlates with tumor cell growth
and invasiveness in vitro and tumor growth and metastasis in the
orthotopic injection models of pancreatic cancer (3, 4). MUC1overexpressing cells (S2-013.MUC1) produced larger tumors than
the mock-transfected S2-013 cells (S2-013.Neo), indicating that
MUC1 overexpression facilitates tumor growth (3). Pancreatic
cancer cells metastasize to liver, lung, lymph nodes, and other
tissues in patients with pancreatic cancer. MUC1 overexpression
in pancreatic cancer cells signiﬁcantly enhances the number of
metastases in lymph nodes and lungs in orthotopic implantation
models (3). Furthermore, mice lacking MUC1 have a profound
defect in tumor growth and metastasis (1). These mice also have
defects in MAPK activity and oncogenic signaling.
Pancreatic tumors exhibit signiﬁcant levels of desmoplasia that
results in hypoxic microenvironments (10, 11). Hypoxia is known
to stabilize the activity of hypoxia-inducible factors (HIFs) that
reprogram cancer cell metabolism to facilitate cancer cell growth
in harsh environments (12–14). HIFs can also be stabilized by
several oncogenes, which act through hypoxia-independent
mechanisms. HIF-1α activates transcription of several genes
regulating glucose uptake, glycolysis, and ﬂux through the tricarboxylic acid cycle. Thus, increased protein levels of HIF-1α
result in increased glucose metabolism through the glycolytic
pathway, but reduced entry of glucose into the TCA cycle (12).
Such metabolic alterations provide the tumor cells with increased biomass production, thus enhancing proliferation.
Here, we present data implicating MUC1 as a facilitator of
glucose uptake and glycolysis in pancreatic cancer cells. In addition, we demonstrate that MUC1 physically occupies promoter
regions and regulates expression of multiple metabolic genes.
Furthermore, we show that MUC1 enhances HIF-1α stabilization and activity in pancreatic cancer cells. Our metabolomic
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analysis demonstrates that MUC1 acts as a master regulator of
the metabolic program in pancreatic cancer.
Results
MUC1 Physically Occupies Promoters of Key Metabolic Enzymes and
Regulates Their Activity. Activation of MUC1.CT signaling in re-

sponse to various growth factors leads to differential gene expression (2). To further investigate the mechanism by which
MUC1.CT activation triggers differential gene expression, we
performed ChIP-chip promoter analysis. We used CT2 mAb,
which recognizes MUC1.CT, to pull down the sonicated DNA
elements that were occupied by MUC1 in S2-013.MUC1F
cells, and the DNA elements were then identiﬁed by performing a promoter microarray analysis, as described previously (7). Results from these studies showed that the
promoters of several metabolic genes are physically occupied by
MUC1 (Fig. S1 A and C). We conﬁrmed ENO1 and PGM2
promoter occupancy by MUC1 in independent ChIP studies
(Fig. S1 B and D).
MUC1 Regulates Expression of Glycolytic Genes. To determine if
MUC1 regulates the expression of glycolytic genes, we performed real-time quantitative PCR (qPCR) analysis of RNA
extracted from control (S2-013.Neo), MUC1-overexpressing (S2013.MUC1), vector control [FG.shScr (scrambled control)], and
MUC1-knockdown (FG.shMUC1) cells cultured under normoxic or hypoxic conditions (at 1% oxygen), which enhance
glycolytic gene expression (15). The relative mRNA expression
levels for HK2, PFKFB2, ENO1, PGK1, PGM2, and LDHA are
shown in Fig. S2A. These results indicate that MUC1 has an
additive role with hypoxia on some of the glycolytic gene promoters (e.g., LDHA), whereas, on others (e.g., PGK1, PGM2),
there is synergism between MUC1 and hypoxia.
MUC1 Regulates Glucose Uptake and Lactate Production in Pancreatic
Cancer Cells. As MUC1 occupies promoters of multiple genes

involved in glycolysis, we then determined the effect of MUC1
expression on glucose uptake and lactate production. To achieve
this, we performed glucose uptake assays in S2-013.MUC1 or S2013.Neo cells by using [3H]2-deoxyglucose (DG). Cells treated
with labeled and excess unlabeled 2-DG were used as controls to
set a baseline for nonspeciﬁc tritium uptake. After normalization
for total cell count, we observed a twofold increase in glucose
uptake by S2-013.MUC1 in comparison with S2-013.Neo cells
(Fig. S2B). Similarly, we observed a more than twofold reduction
in glucose uptake upon knockdown of MUC1 expression in FG.
shMUC1 cells in comparison with FG.shScr (Fig. S2C). These
results demonstrate that MUC1 expression facilitates glucose
uptake in pancreatic adenocarcinoma cells. Levels of lactate, an
end product of aerobic glycolysis, were also similarly modulated
by MUC1 (Fig. S2 B and C).
MUC1 Regulates in Vivo Glucose Uptake in an HIF-1α–Dependent
Manner. Next, we sought to determine if the differences in the

rate of glucose uptake were not simply an artifact of cell culture.
To achieve this, we implanted the S2-013.MUC1 or S2-013.Neo
cells orthotopically into the pancreas of athymic female nude
mice. Three weeks later, the mice were injected with IR800 dyecoupled 2-DG (IRDye 800CW 2DG; LI-COR Biosciences). The
mice were imaged 24 h after injection. We observed signiﬁcantly
higher glucose uptake by tumors generated from S2-013.MUC1
cells than the tumors generated from S2-013.Neo cells (Fig. 1A).
The glucose uptake values were quantiﬁed by normalizing to the
tumor size (Fig. S3) determined by euthanizing the animals after
glucose measurements (Fig. 1B). Similar results were obtained
with orthotopically implanted Capan1.MUC1 and Capan1.neo
cells (Fig. 1B). However, MUC1-mediated increase in glucose
uptake was signiﬁcantly diminished by HIF-1α knockdown (Fig.
13788 | www.pnas.org/cgi/doi/10.1073/pnas.1203339109

Fig. 1. MUC1 regulates in vivo glucose uptake and expression of glycolytic
genes. (A) Glucose uptake by tumors formed by orthotopically implanted
S2-013.Neo.shScr (scrambled control), S2-013.MUC1.shScr (scrambled control), or S2-013.MUC1.shHIF-1α (HIF-1α knockdown). Orthotopic xenograft
tumors in athymic nudes were imaged with IRDye 800CW 2DG. Arrowheads indicate the tumors. (B) Quantiﬁcation of in vivo glucose uptake by
tumors (normalized to tumor size). (C ) Immunohistochemical staining of
formalin-ﬁxed parafﬁn-embedded tumor sections reveals increased expression of HIF-1α, GLUT1, and LDHA and increased nuclear Ki67 staining
in S2-013.MUC1 cells in comparison with S2-013.Neo cells. Arrowheads
point to nuclear Ki67 staining. (D) Immunoﬂuorescence staining for hypoxia (EF5, red), HIF-1α (green), and nuclei (DAPI) in tumor sections from
S2-013.Neo, S2-013.MUC1, and S2-013.MUC1.shHIF-1α–implanted mice
(*P < 0.05 and **P < 0.01).

1B). Also, we determined the expression of genes involved in
aerobic glycolysis in the tumor sections from orthotopic implantation models with S2-013.Neo and S2-013.MUC1 cells (Fig.
1C). The expression of HIF-1α, GLUT1, and LDHA was signiﬁcantly more enhanced in tumors from S2-013.MUC1 cells in
comparison with that of S2-013.Neo cells. Also, S2-013.MUC1
cells exhibited higher staining levels of Ki67, a marker of cell
proliferation, compared with the S2-013.Neo cells (Fig. 1C). The
increases in the expression of glycolytic genes were abrogated by
HIF-1α knockdown (Fig. 1C). Reciprocally, MUC1 knockdown
in orthotopically implanted cells expressing naturally high levels
of MUC1 (Capan2.shMUC1 vs. Capan2.shScr) demonstrated
decreased glucose uptake (Fig. S4). Immunoﬂuorescent EF5
staining indicated that, although the hypoxia levels were similar
in the different tumor groups, MUC1 expressing tumor sections
demonstrated enhanced HIF-1α levels (Fig. 1D). These results
Chaika et al.

MUC1 Regulates Expression/Stability and Activity of HIFs. As our
data indicated an additive effect of hypoxia on MUC1-mediated
transcriptional activation of glycolytic genes, we next examined if
MUC1 modulated the stability of hypoxia-inducible transcription
factors at protein level. By performing Western blot analysis, we
evaluated if culturing S2-013.MUC1 cells under hypoxia-mimicking conditions (CoCl2, which stabilizes HIFs) differentially
altered the expression of HIF-1α and HIF-2α in comparison with
the control S2-013.Neo. Our CoCl2 dose-course (Fig. S5A) and
time-course (Fig. S5B) experiments suggest that MUC1 expression enhances expression/stabilization of HIF-1α and HIF-2α in
pancreatic cancer cells. However, the increased expression of
HIF-1α under conditions of MUC1 overexpression is not caused
by changes in mRNA levels of HIF-1α or the prolyl hydroxylase
domain-containing proteins (PHDs)/von Hippel–Lindau tumor
suppressor protein (VHL) that regulate HIF-1α turnover (Fig.
S6). S2-013.MUC1 cells also demonstrated increased expression
of HK2, GLUT1, and PDK1 at protein level, in contrast to the
S2-013.Neo cells (Fig. S5C). We performed lentiviral shRNAmediated knockdown of HIF-1α in S2-013.Neo and S2-013.
MUC1 cells. HIF-1α knockdown, but not scrambled control,
diminished hypoxia mimetic-induced expression of the glycolytic
gene HK2 (Fig. S5D). Furthermore, by performing promoterreporter assays by using hypoxia response element (HRE)-containing human enolase (ENO) 1 promoter-Luciferase reporter
constructs, we observed that S2-013.MUC1 cells exhibited higher
HRE-promoter activity under treatment with DMOG, which
inhibits PHDs and stabilizes HIF-1α (Fig. S5E) (16). Strikingly,
even when transfected with constitutively active HIF-1α, which
has been rendered resistant to proteasomal degradation via deletion of part of the oxygen-dependent domain of HIF-1α and
mutation of speciﬁc prolyl residues (17), S2-013.MUC1 cells
exhibited higher activity than S2-013.Neo cells (Fig. S5E). Thus,
we can infer that MUC1 enhances HIF-1α activity, independent
of its effect on HIF-1α expression levels. MUC1 expression also
enhanced hypoxia-induced glucose uptake in S2-013 and Capan1
pancreatic cancer cell lines (Fig. S5F-G). Knockdown of HIF-1α
in S2-013.MUC1 cells reverted MUC1 overexpression-induced
increase in glucose uptake (Fig. S5F). Reciprocally, the expression levels of MUC1 were also induced by hypoxic conditions in

a HIF-1α–dependent manner (Fig. S5 H and I). Furthermore,
knockdown of MUC1 in Capan2 pancreatic cancer cell line diminished hypoxia-induced increase in the expression levels of
HIF-1α, HK2, and GLUT1 (Fig. S7 A and B). Also, MUC1
knockdown in Capan2 diminished glucose uptake and lactate
production (Fig. S7 C and D). As MUC1 and HIF-1α facilitate
expression of some of the same glycolytic genes, we tested if the
synergist activity is a result of their physical interaction. Proximity ligation assays (PLAs) demonstrate signiﬁcant MUC1 and
HIF-1α interaction in S2-013.MUC1 and FG cells under HIF-1α
stabilizing conditions (Fig. 2 A and B). Also, we could coimmunoprecipitate HIF-1α with MUC1 by using an mAb against
MUC1.CT, from S2-013.MUC1 cells treated with CoCl2 or
solvent control (Fig. 2C).
MUC1 Facilitates Hypoxia-Dependent Recruitment of HIF-1α and p300
to Glycolytic Gene Promoters. Next, we sought to ask if MUC1

expression enhances occupancy of glycolytic gene promoters by
HIF-1α. To achieve this, S2-013.Neo and S2-013.MUC1 cells were
cultured under normoxic or hypoxic conditions (1% oxygen) for 4
h and subjected to ChIP assays with HIF-1α Ab. qPCR assays with
the immunoprecipitated chromatin indicated increased HIF-1α
occupancy on ENO1 and PGM2 glycolytic gene promoter regions
containing functional HREs; −109/+44 (i.e., ﬂanking sequence
and 44 nt inside the transcription start site) for ENO1 and −63/
+52 for PGM2 (Fig. 3A) (16). No enrichment was observed for
the distal regions. Furthermore, MUC1 coimmunoprecipitated
with p300, a HIF-1α coactivator, in a hypoxia-dependent
manner (Fig. 3B). ChIP assays revealed p300 occupancy at
ENO1 and PGM2 HRE regions, which was signiﬁcantly enhanced by hypoxic conditions. The p300 occupancy was further
enhanced by MUC1 overexpression in a hypoxia-dependent
manner (Fig. 3C). The levels of histone H3 acetylated at lysine9 (H3K9-ac) at ENO1 and PGM2 HREs was also signiﬁcantly
enhanced by MUC1 overexpression in a hypoxia-dependent
manner (Fig. 3D). MUC1 overexpression had no effect on total
cellular levels of H3K9-Ac or histone 3 (Fig. 3E).
MUC1 as Global Metabolic Regulator. To identify the effect of
MUC1 on global metabolite levels in pancreatic adenocarcinoma
cells, we performed NMR-based differential metabolomic studies. Principle component analysis of one-dimensional 1H NMR
spectra obtained from unlabeled S2-013.Neo and S2-013.MUC1

Fig. 2. Interaction of MUC1.CT with HIF-1α. (A) PLA
with Abs against MUC1.CT (CT2) and HIF-1α demonstrate increased interaction of MUC1 with HIF-1α
under conditions of MUC1 expression and 6 h CoCl2
treatment. Arrowheads point to the interaction
spots. Right: 3D localization of interaction spots in
S2-013.MUC1 cells under CoCl2 treatment. (B)
Quantiﬁcation of interaction spots per cell in S2-013.
Neo, S2-013.MUC1, FG.shScr, and FG.shMUC1 cells
under conditions of 6 h CoCl2 treatment or control.
(C) Coimmunoprecipitation of HIF-1α along with
MUC1 from Nonidet P-40 extracts of 6 h CoCl2
treated or control S2-013.MUC1 cells. Immunoprecipitations with isotype IgG were performed as a control (*P < 0.05, **P < 0.01, and ***P < 0.001).
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conﬁrm that MUC1 overexpression enhances glucose uptake in
pancreatic cancer cells.

Fig. 3. MUC1 facilitates HIF-1α recruitment to glycolytic gene promoters. (A) Occupancy of ENO1 and
PGM2 promoters by HIF-1α was conﬁrmed by ChIP
using anti–HIF-1α Ab or IgG control, followed by
qPCR analysis. Enrichment of proximal and distal
ENO1 and PGM2 promoter regions from S2-013.Neo
and S2-013.MUC1 cells under normoxic or hypoxic
conditions (1% O2, 6 h) was compared with that
from S2-013.Neo under normoxic conditions. (B)
Coimmunoprecipitation of p300 along with MUC1
from Nonidet P-40 extracts of 6 h hypoxia-treated
or control S2-013.MUC1 cells. M, marker lane; WCL,
whole-cell lysate. (C) Occupancy of ENO1 and PGM2
promoters by p300 was conﬁrmed by ChIP using
anti-p300 Ab or IgG control, followed by qPCR
analysis. Enrichment of proximal and distal ENO1
and PGM2 promoter regions from S2-013.Neo and
S2-013.MUC1 cells under normoxic or hypoxic conditions was compared with that from S2-013.Neo
under normoxic conditions. (D) ChIP assays were
performed with IgG or anti-acetylated H3K9 (H3K9Ac) antibody. (E) Immunoblotting to determine the
total cellular levels of acetylated lysine 9 residue in
histone 3 (H3K9-Ac) and the protein expression
levels of histone 3 (H3) and MUC1 under hypoxic
conditions in S2-013.Neo and S2-013.MUC1 cells.
Tubulin was used as a loading control. (Normalized
relative values are presented as vertical bars ± SEM;
*P < 0.05, **P < 0.01, and ***P < 0.001).

cell lysates indicated that they cluster into two separate groups
and that they can be metabolically differentiated (Fig. 4A). We
then labeled S2-013.MUC1 and S2-013.Neo cells with 13C6-glucose and performed 2D 1H-13C heteronuclear single quantum
coherence (HSQC) NMR experiment to identify the 13C-labeled
metabolites in the cell extracts. Pathway information for each of
the metabolites was obtained from Cytoscape and Metscape. The
metabolites were linked with the nearest possible metabolite in
the pathway. These studies identiﬁed MUC1-regulated metabolites involved in multiple metabolic pathways in pancreatic cancer
(Fig. 4B). Overall, metabolites involved in glucose metabolism,
amino acid metabolism, and TCA cycle were found to be altered
by overexpression of MUC1, suggesting their role in MUC1mediated induction of cell growth and proliferation in pancreatic
adenocarcinoma (Fig. 4C). Flux through the pentose phosphate
pathway, which contributes to nucleotide synthesis, is enhanced
by MUC1 overexpression. Also, we observed increased levels of
several amino acids, including glutamine, in MUC1-overexpressing S2-013 cells. When subjected to glutamine-deprived
conditions, S2-013.MUC1 cells demonstrated increased cell
growth, in a hypoxia-dependent manner, in comparison with the
controls (Fig. 4D). However, MUC1 expression did not provide
any growth advantage under glucose-deprived conditions.
13790 | www.pnas.org/cgi/doi/10.1073/pnas.1203339109

Discussion
In the present study, we report the ﬁnding that MUC1 regulates
metabolism in pancreatic cancer cells. First, we demonstrated
that MUC1 physically occupies the promoter elements of multiple genes involved in glycolysis and glucose metabolism in
pancreatic cancer cells (Fig. S1). To conﬁrm if physical occupancy correlates with transcriptional activation of the genes, we
performed qPCR analyses. The qPCR analyses indicated that
MUC1 facilitates expression of multiple key glycolytic genes at
mRNA level and that the effect is further pronounced under the
hypoxic conditions, indicating a role of HIF factors. Assaying
MUC1-overexpressing S2-013 cells or MUC1-knockdown FG
cells, along with control cells, indicated that MUC1 expression
enhanced glucose uptake and lactate production, in contrast to
control cells. Furthermore, MUC1 expression correlated with
increased glucose uptake in vivo in the orthotopic xenograft
implantation model of pancreatic cancer. Also, MUC1 expression correlated with increased expression of glucose metabolic
enzymes such as GLUT1 and LDHA. These results indicate that
MUC1 expression transcriptionally activates glycolytic genes and
thus facilitates increased glucose uptake and consumption in
pancreatic cancer cells. These ﬁndings correlate well with the
Chaika et al.

previous studies that suggest a role of MUC1 in modulating
growth and invasive properties in multiple cancer types (3, 4).
Increased tumor cell metabolism has been identiﬁed as a hallmark of cancer and a requirement for rapid tumor cell growth.
Our data demonstrate that MUC1 interacts with HIF-1α and
regulates the stability/activity of the latter. HIF-1α stability is
regulated by prolyl hydroxylation. Under well-oxygenated conditions, HIF-1α is hydroxylated on Pro-402 and/or Pro-564 by
PHD2, which uses oxygen and 2-oxoglutarate, also known as
α-ketoglutarate, as substrates in a reaction that generates CO2
and succinate as byproducts (12). Prolyl hydroxylation of HIF-1α
triggers its interaction with the von Hippel–Lindau tumor
suppressor protein, which recruits an E3-ubiquitin ligase that
targets HIF-1α for proteasomal degradation. Under hypoxic
conditions, the prolyl hydroxylation is inhibited by substrate
(i.e., O2) deprivation and/or the mitochondrial generation of
reactive oxygen species, which may oxidize Fe(II) present in
the catalytic center of the hydroxylases (12). Furthermore,
metabolic alterations that result in depletion of oxoglutarate
facilitate stabilization of HIF-1α. Our metabolomic data indicates that MUC1 expression decreases the intracellular levels
of 2-oxoglutarate, which may be the reason for increased stabilization of HIF-1α under conditions of MUC1 expression.
Treatment of S2-013.Neo or S2-013.MUC1 cells with excess
2-oxoglutarate diminishes MUC1-dependent increase in the
levels of HIF-1α (Fig. S8).
Previous studies have demonstrated that MUC1 itself is a target of HIF-1α (18). Thus, increased stabilization of HIF-1α
might be a part of a positive feedback loop that may serve to
promote tumorigenesis and metastasis in cancer cells. Our
studies are in contrast to the previous studies by Yin et al. in
HCT116 and ZR-75-1 cells, in which the authors demonstrate
PHD3 down-regulation-mediated decreased stabilization of
HIF-1α by MUC1 (19). Interestingly, even Yin et al. identiﬁed
that MUC1 causes a decrease in the expression of PHD2 (19),
the major prolyl hydroxylase for HIF-1α in most cell types.
However, the decreased stabilization of HIF-1α by MUC1 in
their studies could reﬂect cell type-speciﬁc dependence of HIFChaika et al.

1α on PHD3. Regardless of which PHD is the major regulator
of HIF-1α stabilization, 2-oxoglutarate is a critical substrate for
the reaction. Hence, our metabolomic studies indicating a decrease in the levels of 2-oxoglutarate by MUC1 clearly suggest
that MUC1 causes a decrease in PHD activity that results in
HIF-1α stabilization in pancreatic cancer cells. Our mRNA
expression data indicating an increase in the levels of PHD1-2
as a result of MUC1 suggests that the cells try to recover from
the decreased PHD activity by increasing the mRNA levels
(Fig. S6). A similar phenomenon is observed under hypoxic
conditions in which PHD activity is signiﬁcantly depleted as
a result of a lack of oxygen substrate.
Furthermore, MUC1 physically occupies the promoter regions
of and selectively enhances the transcription of some of the glycolytic genes in a HIF-dependent manner. Our studies indicate
that MUC1 co-occupies promoter elements of glycolytic genes
along with HIF-1α. Also, MUC1 modulates glycolytic promoter
occupancy by HIF-1α and p300 and thus H3K9 acetylation status
and HIF-1α transcriptional activity in pancreatic cancer. There are
at least two potential mechanisms whereby MUC1 could modulate the effects of hypoxia signaling through the HIF transcription
factors: by regulating HIF stability and interaction partners and
thereby directly modifying HIF signaling; and by direct signaling
through the MUC1.CT, in a manner in which MUC1 directly
associates with transcription factors (e.g., p53, β-catenin, and
ERα) (2). Our studies demonstrate that MUC1 regulates HIF
stability, HIF activity, p300 recruitment, and histone acetylation
status on HIF-inducible promoters and that MUC1 can induce the
expression of hypoxia-inducible genes in an HIF-dependent
manner. The MUC1-dependent increase in p300 recruitment and
H3K9 acetylation at HRE elements of glycolytic gene promoters
may explain MUC1-mediated increase in HRE-luciferase activity
under expression of constitutively stabilized HIF-1α.
Our NMR-based metabolomics studies indicate that MUC1
facilitates glucose and amino acid metabolism in pancreatic
cancer cells. We observed decreased accumulation of glucose,
glycolytic intermediates, and lactate in S2-013.MUC1 cells, in
contrast to S2-013.Neo cells. Metabolomic studies indicate the
PNAS | August 21, 2012 | vol. 109 | no. 34 | 13791
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Fig. 4. MUC1 regulates metabolite levels in pancreatic cancer cells. (A) Three-dimensional principal
component analysis scores plot comparing S2-013.
Neo cells (black) with S2-013.MUC1 cells (red). (B)
Heat map generated from the normalized-mean
peak intensities for each metabolite identiﬁed from
the triplicate set of 2D 1H-13C HSQC NMR experiments. The normalized-mean intensities are plotted
on a color-scale from 0% (red) to 100% (green).
Dendogram depicts hierarchal clustering of relative
metabolite concentration changes between the
S2-013.MUC1 and S2-013.Neo cells (*P < 0.05 and
***P < 0.001; metabolites in italics have lower
levels of conﬁdence in NMR peak assignment). (C )
Metabolic pathway depicting the metabolites
identiﬁed in the S2-013.MUC1 and S2-013.Neo
cellular metabolome by the 2D 1H-13C HSQC NMR
experiments. Three replicates of S2-013.MUC1 and
S2-013.Neo cell cultures were used for metabolite
identiﬁcation. Dark green arrows correspond to
metabolites with an increased concentration in S2013.MUC1 cells relative to S2-013.Neo cells. Arrows
colored red correspond to metabolites with a decreased concentration in S2-013.MUC1 cells relative
to S2-013.Neo cells. Metabolic genes up- or downregulated by MUC1 expression are indicated by
green and red, respectively. Most glycolytic genes
are not depicted for clarity. (D) Cells (5 × 104) were
seeded and cultured under normoxic or hypoxic
conditions (1% O2) in regular or glucose/glutamine-deprived media for 3 d. Cell counts at day 3 are indicated by vertical bars ± SEM (n = 3; *P < 0.05 and
***P < 0.001 vs. counts of S2-013.Neo cells for that condition).

kinetics of metabolic reactions in the cells. Hence, the decreased
accumulation of glucose, glycolytic intermediates, and lactate,
despite higher glucose uptake rate and increased secretion of
lactate in the culture media, indicates that S2-013.MUC1 cells
have faster glucose turnover, in contrast to S2-013.Neo cells. It is
evident that glucose and amino acid metabolic pathways are
critical for the production of biosynthetic intermediates, and thus
for rapid tumor cell growth (20). We observed increased ﬂux
through glycolysis and pentose phosphate pathways. Increased
levels of ribose 5-phosphate may account for increased nucleotide biosynthesis in S2-013.MUC1 cells in comparison with the
S2-013.Neo cells. Also, we observed increased levels of amino
acids, including glutamine, which may explain MUC1-dependent
increase in cell growth even under conditions of glutamine
deprivation. In fact, our analysis of Ki67 levels in tumor sections
suggest that MUC1-facilitated HIF-1α stability/activity promotes
cancer cell growth under hypoxic conditions in the pancreatic
tumor model. These ﬁndings are critical because HIF-1α is a key
modulator of glycolysis in cancer and HIF-1α has been implicated in tumorigenesis. Furthermore, compared with the normal
tissues, which are well oxygenated, metastasizing tumor cells
intermittently switch between hypoxic and aerobic conditions.
This leads to stabilization and activation of HIF-1α, which in turn
facilitates aerobic glycolysis in tumors.
In summary, we have presented ﬁndings that MUC1 serves as
a metabolic regulator that facilitates the transcription of multiple
genes involved in the glucose metabolic pathways. Also, we
present a mechanistic relationship between MUC1 and HIF-1α,
whereby MUC1 may increase the stability of HIF-1α by diminishing the levels of 2-oxoglutarate. We also present evidence that
MUC1 physically interacts with HIF-1α and p300 in a hypoxiadependent manner, and enhances promoter occupancy of the HIF1α and p300 on glycolytic gene promoters. The interrelationship
between MUC1–HIF-1α oncogenic signaling networks serves to
facilitate tumor growth and metastasis and could present a potential therapeutic target for the treatment of malignant diseases
that rely upon MUC1 and HIF-1α.

ChIP and qPCR Assays. ChIP assays and qPCR assays were performed as described in SI Materials and Methods. The qPCR primer sequences are given in
Table S1. For ChIP qPCR analysis, values were normalized to a genomic region located within the β-glucuronidase (GUSB) gene and expressed as fold
increase vs. enrichment detected by using IgG as published previously (7).
The average expression ± SEM was reported.
Immunoblotting, Immunoprecipitation, and PLAs. Western blotting and
immunoprecipitations were performed as previously described (21, 22). The
membranes were probed with primary antibodies against HIF-1α (Santa Cruz
Biotechnology), MUC1 (Abcam), GLUT1 (Abcam), HK2 (Cell Signaling Technology), and LDHA (Abcam). In situ PLA experiments were performed as
described in SI Materials and Methods.
Animal Studies, Immunohistochemistry, and Hypoxia Imaging. Animal studies,
immunohistochemistry and hypoxia imaging were performed as described in
SI Materials and Methods.
Metabolomic Analysis. S2-013.Neo or S2-013.MUC1 cells (1.5 × 107) were used for
NMR-based metabolomic analysis. The details of metabolite extraction and onedimensional 1H NMR spectra and 2D 1H-13C HSQC spectra analysis are described
in SI Materials and Methods. The peaks were assigned to individual metabolites
by using the chemical shift references from the Human Metabolomics Database
(23). KEGG (24) database was used for drawing the metabolite network.
Statistical Analysis. Nonparametric Kruskal–Wallis tests were used to compare differences between cell lines. If the overall Kruskal–Wallis test indicated a difference in cell lines, a Wilcoxon rank-sum test was performed
for each pairwise comparison of interest. Student t test was used when
appropriate. P < 0.05 was considered signiﬁcant.

Cells and Reagents. Cell culture media and conditions are described in SI
Materials and Methods. DMOG (Cayman Chemical) was dissolved in DMSO,
and CoCl2 (Sigma) was dissolved in DMEM.
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Cells and Reagents. Capan1 and Capan2 cells were obtained from
American Type Culture Collection. S2-013 is a cloned subline of
a human pancreatic tumor cell line (SUIT-2) derived from
a liver metastasis (1). The S2-013 cells were cultured as previously described (2). FG cell line is a liver metastatic derivate
of colo357 cells (3). shRNA-mediated knockdowns of MUC1
and hypoxia-inducible factor (HIF)-1α were established by using the target sequences described elsewhere (4, 5). MUC1overexpressing variants of S2-013 and Capan1 cells have been
described previously (6, 7).
Glucose Uptake Assay. Cells (5 × 104) were seeded per well in a 24-

well plate. Twelve hours later, the cells were starved for glucose
for 2 h and then incubated for 20 min with 1 μCi [3H]2-deoxyglucose (DG) for a glucose uptake assay. Cells were lysed with
1% SDS and the lysates were counted for [3H] by using a scintillation counter. Cells treated with labeled and excess unlabeled
2-DG were used as controls to set a baseline for nonspeciﬁc
tritium uptake. The results were normalized to the cell counts for
treated and untreated groups. Data are presented as the mean
value of triplicate values of glucose uptake normalized with
control cells.
Lactate Assay. Lactate levels secreted in the media were ana-

lyzed by colorimetric assays. The assay was performed as per
the manufacturer’s protocol by using a Lactate Assay Kit II
(BioVision).
Luciferase Assays. Hypoxia response element (HRE) luciferase
plasmid was obtained from Addgene (8). PGL2 basic was used
as a control plasmid for transfection in luciferase studies. A
dual luciferase reporter assay (Promega) was used to detect
promoter activity in this study. A synthetic Renilla luciferase
reporter plasmid pRL-SV40 (Promega) was used as a control
for transfection efﬁciency. The assays were performed as described previously (7). Each experiment was performed three
times in triplicate.
ChIP and Real-Time PCR Assays. ChIP assays were performed as
described previously (6). cDNA was generated by using SuperScript III First-strand Synthesis Kit (Invitrogen). Reactions
containing 2.0 μL cDNA for gene expression analysis or 3.0 μL
puriﬁed chromatin for ChIP analysis were prepared in SYBR
Green master mix (Applied Biosystems) and subjected to
quantitative real-time PCR analysis by using an ABI 7500 thermocycler. Each reaction was repeated in triplicate, and the experiments were repeated at least twice to conﬁrm reproducibility.
Values were obtained for the threshold cycle (Ct) for each gene
or genomic region, and data were analyzed using the standard
curve method. For real-time PCR analysis, values were normalized to the expression of β-actin, and average expression ±
SEM was reported. Primer sequences are given in Table S1.
For ChIP PCR analysis, values were normalized to a genomic
region located within the β-glucuronidase (GUSB) gene and
expressed as a fold increase vs. enrichment detected by using
IgG, as published previously (6). The average expression ±
SEM was reported.
Proximity Ligation Assay. In situ proximity ligation assay (PLA)
experiments were performed by using DuoLink II (Olink Bioscience). Cells were incubated overnight at 4 °C with anti-MUC1
Chaika et al. www.pnas.org/cgi/content/short/1203339109

(Abcam) diluted 1:500 and/or anti–HIF-1α (Santa Cruz Biotechnology) diluted 1:50 in blocking buffer. Samples were then
washed with PBS solution and incubated with PLA probes DII
anti-mouse/hamster MINUS, DII anti-mouse/hamster PLUS,
DII anti-rabbit MINUS, or DII anti-rabbit PLUS in combinations suitable for single or dual recognition. Control experiments
were included by omitting the primary antibody used for single
recognition PLA or either one of the primary antibodies used in
double recognition PLA. The subsequent washing steps, ligation,
rolling-circle ampliﬁcation and ﬂuorescent labeling with DuoLink II Detection Reagent Orange were performed according to
the manufacturer’s instructions (Olink Bioscience). Slides with
PLA samples were mounted in DuoLink II Mounting Media
with DAPI (Olink Bioscience). A Zeiss LSM 510 microscope
equipped with a Zeiss image processing system was used for
confocal imaging. A 63×/1.4 oil objective and sequential scanning with ﬁlters appropriate to each ﬂuorophore was used (420–
480 nm for DAPI, 505–530 nm for EGFP, 560–615 nm for CY3,
and long-pass 560 nm for PLA signals). Images used for PLA
quantiﬁcation were captured and processed with identical settings. PLA signals of individual cells were counted in ﬁve individual confocal images and a minimum of 50 cells per sample.
Tumor Growth and in Vivo Glucose Uptake Studies. Congenitally
athymic female nude mice (NCr-nu/nu) were purchased from the
National Cancer Institute. Mice were treated in accordance with
institutional animal care and use committee guidelines. Cells (5 ×
105) were used for orthotopic injections into the pancreas of
nude mice, as described previously (9). A total of 12 to 14 mice
were used for each cell type/condition. When the tumors were
palpable, the mice were injected i.p. with 100 μL of 10 nM IR800
dye-coupled 2-DG (IRDye 800CW 2DG; LI-COR Biosciences)
with or without glucose (2 g/kg body weight; control). The mice
were imaged 24 h after injection by using Pearl Impulse, a nearIR in vivo imager (LI-COR Biosciences).
Immunohistochemistry and Hypoxia Imaging. Immunohistochemistry was performed by using goat anti-rabbit IgG-AP with Fast-Red
to produce red stain (Picture-Double Staining kit; Invitrogen) per
manufacturer instructions. The following primary antibodies were
used: GLUT1 (Abcam), HIF-1α (Santa Cruz Biotechnology),
Ki67 (Thermo Fisher), and LDHA (Abcam). The stained sections were imaged at 20× under an inverted microscope. Cells
with Ki67-positive nuclear staining were counted in ﬁve random
ﬁelds at 20× magniﬁcation. To image for hypoxia, tumor-bearing
animals were injected with EF5 at 3 h before euthanasia (10).
After the animals were euthanized, tumor sizes were measured
with calipers. Flash-frozen tumor sections were then stained with
cy3-conjugated anti-EF5 serum, Alexa-488 anti–HIF-1α, and
DAPI. Stained sections were imaged for immunoﬂuorescence.
Extraction of Metabolites. S2-013.Neo or S2-013.MUC1 cells (15 ×

106) were harvested from the culture plate by trypsinization. The
harvested cells were then osmotically lysed in sterile water and
sonicated. The cell lysates were stored in a freezer at −80 °C until
extraction. Frozen cell lysates were lyophilized to dryness and
suspended in 1 mL methanol. The suspension was vortexed to
mix the cell lysates with the methanol thoroughly. The samples
were then centrifuged at 18000 × g for 1 min to spin down the cell
debris. The supernatant was lyophilized by using a freeze dryer
(Labconco). The dried samples were dissolved by using 600 μL
deuterated 50 mM potassium phosphate buffer, pH 7.2 (un1 of 8

NMR Data Analysis. The principal component analysis for 1D 1H
NMR spectra was generated using SIMCA P+12 (Umetrics). 1D
1
H NMR spectra were processed by using ACD/1D NMR
manager, version 12.0 (Advanced Chemistry Development).
After the residual water peaks were removed, the spectra were

integrated using intelligent binning with a bin size of 0.025 ppm.
The noise regions were removed by changing the value of those
bins to zero. Each NMR spectrum was mean-centered and autoscaled by the SD as stated by Zhang et al. (14). The z-score
data of each bin were used for principal component analysis.
Two-dimensional 1H-13C HSQC spectra were processed by
using the NMRPipe software package (15). Peak picking and
peak matching were performed by using NMRViewJ Version 8.0
(16). The data were preprocessed in two steps. The ﬁrst step was
scaling. The intensity of each peak was divided by the mean intensity of all picked peaks for each spectrum. The second step
was normalization. The mean scaled intensity of each peak was
also divided by the maximum intensity of the matched peak from
corresponding spectra (triplicates of S2-013.Neo and S2-013.
MUC1 cell lysates). The intensity of the peak across the triplicates in both groups was set to a range of 0 to 100. These normalized-mean peak intensities correspond to relative metabolite
concentrations. The scaled mean intensity across each peak for
the triplicate spectra for each group (S2-013.Neo and S2-013.
MUC1) was compared to identify a variation in the mean difference in peak intensity. For metabolites that had multiple
peaks, an average was taken by combining the intensities of all
the peaks that belonged to that metabolite in a given replicate.
The comparisons were analyzed by performing two-sample t
tests for each metabolite followed by the Benjamini–Hochberg
method to adjust for multiple comparisons.
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corrected). The solution was transferred to 5-mm-diameter NMR
tubes to conduct the NMR experiment as described as follows.
H and 2D 1H-13C
heteronuclear single quantum coherence (HSQC) NMR experiments were conducted by using a Bruker Avance DRX 500-MHz
spectrometer equipped with a 5-mm triple-resonance cryoprobe (1H, 13C, 15N) with a z-axis gradient. A BACS-120 sample
changer with Bruker Icon software was used to automate the
NMR data collection. The one-dimensional 1H NMR data were
collected at 298 K with 8,192 data points, a spectrum width
of 5482.46 Hz, 32 scan and eight dummy scans, using an excitation sculpting pulse sequence (11). The 2D 1H-13C HSQC
NMR data were collected at 298 K with 128 scans and 16 dummy
scans, with a solvent suppression and a relaxation delay of 0.5 s
(12, 13). The spectrum was collected with 2,048 data points
and a spectrum width of 4,734 Hz in the direct dimension, and
64 data points and a spectrum width of 18,864 Hz in the indirect dimension. Ten replicates of samples were used for 1D
1
H NMR data collection. Triplicates were used for 2D HSQC
experiments.
NMR Experiment. One-dimensional (1D)
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Fig. S1. Occupancy of glycolytic gene promoters by MUC1.CT. (A) ChIP-chip analysis revealed MUC1.CT occupies regions within the ENO1 gene, the proximal
promoter, and upstream regions of the ENO1 promoter. Image from Integrated Genome Browser (Affymetrix) shows two experimental ChIP-chip replicates in
which vertical lines represent individual oligonucleotide probes whose height represents degree of enrichment. Oligonucleotide primer pairs used to conﬁrm
MUC1.CT occupancy are represented by black bars. (B) Occupancy of ENO1 promoter by MUC1.CT was conﬁrmed by ChIP using anti-MUC1.CT antibody (CT2) or
IgG control, followed by quantitative PCR (qPCR) analysis. Enrichment of proximal and distal ENO1 promoter regions was detected in S2-013.MUC1 cells,
whereas no enrichment was observed in S2-013.Neo cells (*P < 0.05). (C) ChIP-chip analysis revealed promoter occupancy of PGM2 promoter by MUC1.CT in two
independent experiments. (D) Occupancy of PGM2 promoter by MUC1.CT was conﬁrmed by ChIP using anti-MUC1.CT antibody (CT2) or IgG control, followed
by qPCR analysis in S2-013.Neo and S2-013.MUC1 cells (*P < 0.05 vs. S2-013.Neo). (E) List of metabolic genes whose promoters are occupied by MUC1.CT, as
determined by ChIP-chip analysis.
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Fig. S2. MUC1 regulates the expression of glycolytic genes and glucose metabolism. (A) qPCR analysis reveals a signiﬁcant increase in the expression of
glycolytic genes at mRNA level by MUC1 under normoxia (indicated by “N”) or hypoxia (indicated by “H”), comparing S2-013.MUC1 (S.MUC1) with S2-013.Neo
(S.Neo) and FG2.shScr with FG2.shMUC1. (B) Glucose uptake and lactate secretion by S2-013.Neo (S.Neo) and S2-013.MUC1 (S.MUC1) cells. Glucose uptake assay
was peformed with [3H]2-DG. Cell lysates were counted for 3H. Cell culture media was used for determining tumor cell-secreted lactate amounts by colorimetry.
(C) Glucose uptake and lactate secretion by FG.shScr and FG.shMUC1 cells (*P < 0.05 and **P < 0.01).

Fig. S3. Effect of MUC1 expression on tumor size: 1 × 106 S2-013.Neo.shScr (scrambled control), S2-013.MUC1.shScr (scrambled control), and S2-013.MUC1.
shHIF-1α (HIF-1α knockdown) cells (A) or Capan1.neo and Capan1.MUC1 (B) were implanted orthotopically in athymic nude mice. Tumor size was measured by
euthanizing the animals at the end of 3 wk and was calculated by multiplying length and breadth. P < 0.05.
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Fig. S4. Effect of MUC1 knockdown on in vivo glucose uptake. (A) Glucose uptake by tumors formed by orthotopically implanted Capan2.shScr (scrambled
control), Capan2.shMUC1.2a (MUC1 knockdown target 2), or Capan2.shMUC1.1a (MUC1 knockdown target 1). (B) Quantitation of in vivo glucose uptake by
tumors formed by orthotopically implanted Capan2.shScr, Capan2.shMUC1.2a or Capan2.shMUC1.1a, FG.shScr, or FG.shMUC1 cells. *P < 0.05, **P < 0.01.
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Fig. S5. Effect of MUC1 on HIF expression and activity. (A) Immunoblotting to demonstrate the effect of different doses of 6 h of hypoxia-mimetic CoCl2
treatment on the expression of HIF-1α and HIF-2α at protein levels in S2-013.Neo and S2-013.MUC1 cells. (B) Effect of different durations of 400 μM dose of
CoCl2 treatment on the expression of HIF-1α and HIF-2α in S2-013.Neo and S2-013.MUC1 cells by immunoblotting. (C) Immunoblotting to demonstrate effect of
MUC1 on expression of HK2, GLUT1, and PDK1 in S2-013.Neo and S2-013.MUC1 cells under treatment with different doses of hypoxia mimetic CoCl2 for 12 h.
(D) HIF-1α knockdown abrogates MUC1-induced up-regulation of glycolytic enzyme HK2. The cells were infected with lentiviral particles carrying HIF-1α
targeting sequences or scrambled control (Scr). Knockdown of HIF-1α and its effect on HK2 expression was determined by Western blotting. (E) Effect of MUC1
on HIF-1α activity was determined by ENO1-HRE promoter-luciferase reporter assays. S2-013.Neo or S2-013.MUC1 cells were transiently transfected for 36 h
with ENO1-HRE-luc, Renilla-luc, constitutively active HIF-1α (CA-HIF-1α), or vector control, and then treated with 1 mM DMOG or PBS solution control for 8 h,
and the luciferase counts were obtained on a luminometer by using a Stop-N-Glow Dual Reporter System. The fold change values presented here have been
normalized with Renilla-Luc activity. (F and G) Effect of MUC1 and HIF-1α on glucose uptake under hypoxia (1% oxygen) was determined by using [3H]2DG in
S2-013.Neo, S2-013.MUC1, S2-013.MUC1.shHIF-1α, Capan1.Neo, or Capan1.MUC1 cells. (H and I) Effect of hypoxia-mediated activation of HIF-1α and HIF-1α
knockdown on MUC1 mRNA levels. S2-013.Neo, S2-013.MUC1 and S2-013.MUC1.shHIF-1α, Capan2.shScr, or Capan2.shHIF-1A cells were cultured under normoxia or 48 h hypoxia, and the mRNA levels of MUC1 were detected by qPCR (*P < 0.05, **P < 0.01, and ***P < 0.001).
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Fig. S6. Effect of MUC1 overexpression on the mRNA levels of PHDs, HIF-1α, von Hippel–Lindau tumor suppressor protein (VHL), and HIF-1AN. qPCR reveals
MUC1 and hypoxia-dependent changes in the mRNA levels of PHDs. qPCR analysis reveals no signiﬁcant change in the expression of HIF-1α, von Hippel–Lindau
tumor suppressor protein, and HIF-1AN at mRNA level by MUC1, comparing S2-013.MUC1 with S2-013.Neo. *P < 0.05, **P < 0.01.

Fig. S7. Effect of MUC1 knockdown on HIF-1α expression and activity. (A) Immunoblotting to demonstrate the effect of 6 h of hypoxia treatment on the
expression of HIF-1α at protein levels in Capan2.shScr and multiple clones of MUC1-knockdown Capan2 (2a, 2b, 2c, and 1a) cells. (B) Immunoblotting to
demonstrate the effect of 12 h of hypoxia treatment on the expression of HK2 and GLUT1 in MUC1 knockdown or control Capan2 cells. (C) Relative glucose
uptake in MUC1-knockdown Capan2 clones relative to Capan2.shScr as determined by [3H]2-DG uptake assays. (D) Amount of lactate secreted by scrambled
control and MUC1-knockdown Capan2 cells as measured by colorimetric assays. *P < 0.05, **P < 0.01.
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Fig. S8. 2-Oxoglutarate (2-OG) abrogates MUC1-induced increase in the protein levels of HIF-1α. S2-013.Neo and S2-013.MUC1 cells were incubated under
normoxic or hypoxic conditions (1% O2). After 2 h hypoxia incubation, the cells were subjected to treatment with 20 μM cycloheximide (CHX) and different
doses of 2-oxoglutarate and then incubated under hypoxia for another 2 h. The levels of HIF-1α, MUC1, and tubulin were determined by immunoblotting.

Table S1. Primer sequences for real-time PCR
Primer
HK2-F
HK2-R
PFKFB2-F
PFKFB2-R
ENO1-F
ENO1-R
PGK1-F
PGK1-R
PGM2-F
PGM2-R
LDHA-F
LDHA-R
HIF1A-F
HIF1A-R
ACTB-F
ACTB-R
HIF1AN-F
HIF1AN-R
EGLN1-F
EGLN1-R
EGLN2-F
EGLN2-R
EGLN3-F
EGLN3-R
EGLN4-F
EGLN4-R
VHL-F
VHL-R
MUC1-F
MUC1-R
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Sequence
GAGCCACCACTCACCCTACT
ACCCAAAGCACACGGAAGTT
ATGACCAACTCCCCGACTCT
TGGACACGTAGGTTTTACCCC
CTGGTGCCGTTGAGAAGGG
GGTTGTGGTAAACCTCTGCTC
TTAAAGGGAAGCGGGTCGTTA
TCCATTGTCCAAGCAGAATTTGA
GAGGCAGTGAAACGACTAATAGC
GAAATTCCAGGTCCCATAGCAG
CTCCAAGCTGGTCATTATCACG
AGTTCGGGCTGTATTTTACAACA
CGTTCCTTCGATCAGTTGTC
TCAGTGGTGGCAGTGGTAGT
GTCCACCGCAAATGCTTCTA
TGCTGTCACCTTCACCGTTC
TTCCCGACTAGGCCCATTC
CAGGGCAGGATACACAAGATTT
GAAGGCGAACCTGTACCCC
CATGCACGGCACGATGTACT
AGGCCCCCAAACGGAAATG
AGGGCACGATATAGTCCAGGG
TCTCCCGAGAGTTGCGAGAAA
AGAGGGAACGATCTACACGAG
ACGCCGCGATCAAGGCTGAC
GCAGCACCCTCTGGCGGATG
GACCTGGAGCGGCTGACA
TACCATCAAAAGCTGAGATGAAACA
CTGCTCCTCACAGTGCTTACAGTTG
TGAACCGGGGCTGTGGCTGG
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